NOC · Q3 2025 Earnings
CautiousNorthrop Grumman
Reported October 21, 2025
30-second summary
Northrop lowered FY25 revenue guidance to $41.7–41.9B (from $42.05–42.25B) on award and program timing delays, yet raised non-GAAP EPS by $0.65 to $25.65–$26.05 and reaffirmed segment operating income and free cash flow. Q3 revenue of $10.42B (+4.3% YoY) and a 1.17x book-to-bill with backlog at $91.4B kept the demand story intact, but Space Systems contracted 6% and management's previously confident "Q4 acceleration" language softened to "ramp at a slightly lower rate." The setup: margin and cash conviction is real, top-line visibility is not.
Headline numbers
EPS
Q3 FY2025
$7.67
Revenue
Q3 FY2025
$10.42B
+4.3% YoY
Free cash flow
Q3 FY2025
$1.26B
Operating margin
Q3 FY2025
11.9%
Key financials
Q3 FY2025| Metric | Q3 FY2025 | YoY | Q2 FY2025 | QoQ |
|---|---|---|---|---|
| Revenue | $10.42B | +4.3% | $10.35B | +0.7% |
| EPS | $7.67 | — | $8.15 | -5.9% |
| Operating margin | 11.9% | — | 13.8% | -190bps |
| Free cash flow | $1.26B | — | $0.64B | +97.2% |
Guidance
Revenue guidance lowered by ~$350M to $41.7-41.9B, but EPS raised $0.65 to $25.65-26.05 on margin expansion; SOI and FCF reaffirmed.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Changes to prior guidance
| Metric | Period | Prior guide | New guide | Δ | Result |
|---|---|---|---|---|---|
| Revenue | FY2025 | $42,050M - $42,250M | $41,700M - $41,900M | -$350M to -$350M at midpoint (lowered by ~0.8%) | Lowered |
| EPS (non-GAAP) | FY2025 | $25.00 - $25.40 | $25.65 - $26.05 | +$0.65 at midpoint (raised by 2.6%) | Raised |
Reaffirmed unchanged this quarter: Segment Operating Income ($4,275M - $4,375M), Free Cash Flow ($3,050M - $3,350M)
Segment KPIs
Q3 FY2025| Segment | Q3 FY2025 | YoY |
|---|---|---|
| Aeronautics Systems | $3.142B | +6.0% |
| Defense Systems | $2.059B | +14.0% |
| Mission Systems | $3.093B | +10.0% |
| Space Systems | $2.698B | -6.0% |
Other KPIs
Q3 FY2025| Segment | Q3 FY2025 |
|---|---|
| Segment Operating Margin Rate | 12.3% |
| Book to Bill Ratio | 1.17 |
| Net Awards | $12.2B |
| Total Backlog | $91.4B |
| Organic Sales Growth | 5% |
Management tone
Narrative arc: Sentinel back on track → Generational tailwinds, broad raise → Margin discipline despite revenue retreat.
The "broad raise" posture of Q2 fractured into selective conviction. Last quarter management raised sales, segment income, EPS, and FCF together — a clean across-the-board signal. This quarter the raise is EPS-only, with revenue cut and SOI/FCF reaffirmed. From the call: "Despite strong growth in the quarter, we are revising our full year revenue guidance down due to delayed timing on certain awards and programs." The shift signals that operational margin leverage is running ahead of plan but customer-side execution velocity has slowed — a meaningful divergence from the "generational shift" framing of Q2.
Q4 ramp language softened. In Q2 management guided Q3 up 3–4% from Q2 and a further Q4 step-up, framed as "accelerating 2H growth." This quarter the language explicitly cooled: "We continue to expect a ramp in Q4 sales in all four segments, but at a slightly lower rate compared to our prior expectations." The directional commitment is intact; the magnitude is not. This is the cleanest tell that internal visibility on near-term award conversion has degraded.
B-21 reframed from "acceleration funded" to "acceleration negotiated, costs higher." Q2 trumpeted the $4.5B reconciliation allocation and improved-return negotiations. This quarter introduced a new wrinkle: "We experienced higher than expected costs to produce the EMD flight test aircraft, which increased our estimate to manufacture the LREP units." Management still expects long-term accretion, but the early-production margin economics are tighter than what Q2's "improved returns" narrative implied. FAXX and B-21 rate acceleration are explicitly excluded from 2026 guidance, deferring the upside catalyst by another quarter.
Capacity narrative expanded but became more capital-intensive. The "unprecedented demand environment" framing was kept, but management added that "our capital deployment strategy is enabling us to meet this demand" — code for sustained CapEx commitments in 2026–2027 on tactical missile motors, large solid rocket motors, and B-21 production capacity. This is consistent with Q2's offensive capacity language but lands differently when revenue is being cut.
Defensive vs. typical. Management is emphasizing execution risk and timing delays even while reporting record backlog and margin expansion — more cautious than NOC's usual posture in a demand-up cycle.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Christine Liwag · Morgan Stanley
What impact could FAXX and B21 acceleration have on 2026 outlook? What is included in current guidance?
Neither FAXX nor B21 acceleration is included in 2026 outlook. FAXX would add revenue but be dilutive to earnings as development revenue has lower margins; B21 ramp would increase sales at zero margin initially but require CapEx investment. Both would be long-term accretive. Guidance would be updated upon clarity on these opportunities.
Seth Seifman · J.P. Morgan
What is the state of maturity and technology readiness for missile warning satellites under Golden Dome? What is the nucleus of missile warning capability—SDA tracking layer, HPTSS, or elsewhere?
Management outlined providing high-fidelity operational analysis to help customer understand missile defense requirements. Golden Dome architecture and spend plan are not public. The opportunity spans existing programs with additional potential and new programs. Clarity expected from Department in coming months on architecture and spend plan.
Ron Epstein · Bank of America Merrill Lynch
What is the status of B21 production rate acceleration discussions? What delays in program awards are occurring and why?
B21 acceleration discussions are active with customer; reconciliation bill includes dollars to support acceleration but actual rates, timing, and outcome depend on negotiations. Government shutdown has delayed discussions but expected to resume. New administration taking time to allocate resources and make determinations; government shutdown impacting decision velocity.
Rich Safran · Seaport
In response to Secretary of Defense request for significant missile production capacity increases, what are Northrop Grumman's plans for further capacity expansion and associated CAPEX timeline?
Northrop has already invested significantly in expanding tactical missile solid rocket motor capacity (more than doubled), breaking ground on another facility coming online in ~2 years. Currently has more capacity than orders; qualifying on additional missile systems (awarded some, in qualification for handful more). Building out capacity for larger solid rocket motors for national security and commercial space applications (Jim 63 XL for ULA/Kuiper). Additional CapEx commitments in 2026-2027.
Sheila Kayalu · Jefferies
Why is Arrow 2025 outlook down slightly despite unchanged B21 award timing? What specific awards were delayed and how should we model 2026 recapture? What is the free cash flow impact of B21 CapEx in 2026?
Arrow outlook reduction was timing of production activity (not lost sales) and percentage-of-completion method adjustments for B21 creating top-line headwinds. B21 expected to remain growth contributor in 2026. Management holding 2026 guidance and will provide cash flow clarity once rate/ramp discussions conclude.
Answers to last quarter's watch list
What to watch into next quarter
Q4 revenue magnitude. Management said "all segments returning to growth" but at "slightly lower rate" than prior expectations. Implied Q4 from new FY guide midpoint is ~$11.0B (FY $41.8B less 9M actuals of ~$30.8B); watch whether reported Q4 hits at least the low end of the FY range, which requires Q4 revenue of $10.85B+. A Q4 print below $10.8B implies another guide-down dynamic was hidden in the FY range.
B-21 deal clarity timeline. Q2 said "coming months." Q3 said "coming months." A third consecutive quarter without disclosed deal terms — or quantified LREP cost impact — would meaningfully erode credibility on the acceleration upside thesis.
Space Systems return to growth. Management committed Q4 returns Space to growth. The segment ran -12% in Q2 and -6% in Q3; a Q4 print at zero or better validates the program-wind-down lap thesis. A negative Q4 Space print would force a rethink of the Golden Dome inflection timing.
Segment OM rate sustainability. 12.3% in Q3 vs. FY framing of "low to mid 11%" means either Q4 normalizes lower or FY guidance was conservative. Watch whether Q4 segment OM holds above 11.5% — if so, the 2026 "low to mid 11%" guide may itself prove conservative.
FAXX or B-21 rate inclusion in 2026 guide. Management explicitly excluded both from 2026. If either gets folded in during the Q4 print, that's a discrete upside catalyst; if neither does and the customer-side delay narrative persists, 2026 growth depends entirely on the in-hand backlog converting on schedule.
EMD/LREP cost reset magnitude. Management flagged higher-than-expected EMD flight test aircraft costs flowing into LREP estimates but didn't quantify. Watch whether Q4 carries a discrete B-21 EAC charge.
Sources
- NOC Q3 2025 earnings release (SEC filing): https://www.sec.gov/Archives/edgar/data/1133421/000113342125000052/noc-09302025xearningsrelea.htm
- NOC Q3 2025 earnings call commentary (as captured in tone and Q&A extraction)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.